Table 11.6a
Immunosuppression Use for Induction, 1996 to 2005
Recipients with Heart Transplants

	Year of Transplant									
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005
Transplants	2,343	2,293	2,348	2,188	2,199	2,202	2,155	2,057	2,016	2,126
With Immunosuppression Info	2,047	2,261	2,318	2,138	2,148	2,152	2,119	2,024	1,967	2,011
Induction Drugs										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	17.0%	18.0%	16.9%	12.0%	9.4%	7.7%	7.0%	7.9%	7.2%	6.8%
OKT3	14.6%	12.4%	9.9%	11.1%	8.7%	8.6%	5.4%	4.6%	3.7%	3.1%
Thymoglobulin	0.0%	0.0%	0.0%	2.5%	6.9%	10.7%	16.2%	12.9%	15.7%	14.9%
Zenapax	0.0%	0.0%	2.9%	7.2%	8.8%	13.4%	11.4%	14.6%	15.7%	15.3%
Simulect	0.0%	0.0%	0.2%	2.5%	5.1%	5.2%	7.0%	9.3%	10.2%	13.8%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.9%	0.7%
No Induction Drugs Recorded	68.7%	70.1%	70.5%	65.7%	62.8%	56.4%	55.1%	52.9%	52.8%	47.8%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.